BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nafissi N, Foldvari M. Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016;8:240-54. [PMID: 26306832 DOI: 10.1002/wnan.1361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Yu N, Lin XJ, Di Q. How to Find Candidate Drug-targets for Antiepileptogenic Therapy? Curr Neuropharmacol 2020;18:624-35. [PMID: 31989901 DOI: 10.2174/1570159X18666200128124338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen DW, Narsineni L, Foldvari M. Multipotent stem cell-derived retinal ganglion cells in 3D culture as tools for neurotrophic factor gene delivery system development. Nanomedicine 2019;21:102045. [PMID: 31255791 DOI: 10.1016/j.nano.2019.102045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Hirooka K, Yamamoto T, Kiuchi Y. Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic target. Neural Regen Res 2021;16:506-7. [PMID: 32985476 DOI: 10.4103/1673-5374.293145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Peynshaert K, Devoldere J, Philips F, Vergauwe F, De Smedt S, Remaut K. Influence of pathogenic stimuli on Müller cell transfection by lipoplexes. Eur J Pharm Biopharm 2020;150:87-95. [PMID: 32173604 DOI: 10.1016/j.ejpb.2020.03.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mallone F, Sacchetti M, Bruscolini A, Scuderi L, Marenco M, Lambiase A. Neurotrophic Factors in Glaucoma and Innovative Delivery Systems. Applied Sciences 2020;10:9015. [DOI: 10.3390/app10249015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Josephy-Hernandez S, Jmaeff S, Pirvulescu I, Aboulkassim T, Saragovi HU. Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm. Neurobiol Dis 2017;97:139-55. [PMID: 27546056 DOI: 10.1016/j.nbd.2016.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
7 Takeuchi H, Inagaki S, Morozumi W, Nakano Y, Inoue Y, Kuse Y, Mizoguchi T, Nakamura S, Funato M, Kaneko H, Hara H, Shimazawa M. VGF nerve growth factor inducible is involved in retinal ganglion cells death induced by optic nerve crush. Sci Rep 2018;8:16443. [PMID: 30401804 DOI: 10.1038/s41598-018-34585-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nafissi N, Foldvari M. Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front Neurosci 2015;9:355. [PMID: 26528114 DOI: 10.3389/fnins.2015.00355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
9 Gauthier AC, Liu J. Epigenetics and Signaling Pathways in Glaucoma. Biomed Res Int 2017;2017:5712341. [PMID: 28210622 DOI: 10.1155/2017/5712341] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
10 Nuzzi R, Tridico F. Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. Front Neurosci 2017;11:494. [PMID: 28928631 DOI: 10.3389/fnins.2017.00494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Chiha W, Bartlett CA, Petratos S, Fitzgerald M, Harvey AR. Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury. Exp Neurol 2020;326:113167. [PMID: 31904385 DOI: 10.1016/j.expneurol.2019.113167] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
12 Claes M, De Groef L, Moons L. Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats. Int J Mol Sci 2019;20:E4314. [PMID: 31484425 DOI: 10.3390/ijms20174314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen DW, Foldvari M. In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment. Drug Deliv Transl Res 2016;6:676-85. [PMID: 27549107 DOI: 10.1007/s13346-016-0324-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xu Y, Yang B, Hu Y, Lu L, Lu X, Wang J, Xu F, Yu S, Huang J, Liang X. Wogonin prevents TLR4-NF-κB-medicated neuro-inflammation and improves retinal ganglion cells survival in retina after optic nerve crush. Oncotarget 2016;7:72503-17. [PMID: 27756890 DOI: 10.18632/oncotarget.12700] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
15 Saragovi HU, Galan A, Levin LA. Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration. Front Cell Neurosci 2019;13:231. [PMID: 31244606 DOI: 10.3389/fncel.2019.00231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]